Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06006819

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Chronic Kidney Diseases Acute Heart Failure Biomarker Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

20 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Cheng Hsin General Hospital

Taipei, Baitou District, 112, Taiwan

Location status: Recruiting

Location contact

Shang Feng Yang, MD

CONTACT

[email protected]

+886-22826-4400 ext. 2481

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hospitalized for acute heart failure

Exclusion criteria

  • initial serum NT-proBNP level <300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis

Treatment and study plan

Primary outcomes

  1. major adverse cardiovascular events

    Time frame: 1 year

    mortality, acute myocardial infarction, acute stroke, and heart failure hospitalization

Secondary outcomes

  1. major adverse kidney events

    Time frame: 1 year

    mortality, new end-stage renal disease, and 30% decline in estimated GFR

Study contacts

Contact information is provided by the study sponsor or research team.

Shang Feng Yang, MD

CONTACT

[email protected]

+886-22826-4400 ext. 2481

Sponsors and collaborators

Lead sponsor

Cheng-Hsin General Hospital

Other

Registry information

Official study title

Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 23, 2023
Registry last updated
Aug 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.